11. Juli 2017
ASCO-Highlights in immunotherapy
Patients with advanced lung cancer, head-and-neck-cancer and melanoma benefit from treatments with immune checkpoint inhibitors nivolumab, pembrolizumab, atezolizumab and ipilimumab.
Patients with advanced lung cancer, head-and-neck-cancer and melanoma benefit from treatments with immune checkpoint inhibitors nivolumab, pembrolizumab, atezolizumab and ipilimumab.